Remedium Capital Partners, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002104501

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 6 positions · Total reported value $170.21M · Top-10 concentration 100.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 57.1% · 1 new · 2 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2025 13F filing, Remedium Capital Partners, LLC disclosed 6 equity positions with a combined reported value of $170.21M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were SYRE ($47.71M), ORKA ($47.05M), APGE ($44.05M). By sector, the heaviest allocations are Health Care 74.1%, Other 25.9%.

Versus the prior quarter, Remedium Capital Partners, LLC opened 1 new positions, trimmed 2 and fully exited 1, a turnover rate of 57.1% of positions.

The largest new positions opened in Q4 2025 were SYRE ($47.71M), ORKA ($47.05M), APGE ($44.05M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • SYRE SPYRE THERAPEUTICS INC · $47.71M
  • ORKA ORUKA THERAPEUTICS INC · $47.05M
  • APGE APOGEE THERAPEUTICS INC · $44.05M
  • JBIO JADE BIOSCIENCES INC · $24.34M
  • CBIO CRESCENT BIOPHARMA INC. · $4.28M
  • DMRA DAMORA THERAPEUTICS INC · $2.77M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Remedium Capital Partners, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Remedium Capital Partners, LLC, based in West Palm Beach, FL, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 6 positions worth $451.63M in total. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: WEST PALM BEACH, FL, United States
  • SEC registration: 801-135411 (status: Approved), registered 2026-05-26
  • Regulatory AUM (Form ADV): $319.00M as of 2026-08-20
  • Website: remediumcp.com

Portfolio Structure

  • 6 positions · $451.63M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 33.0%
  • Average position size: $75.27M

Sector Tilt

  • Health Care 82.8%
  • (classified holdings cover 83% of value)

Quarterly Activity

  • Q2 2026: 2 added
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 74.1%
Other 25.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.46M $47.71M 28.03%
28.03%
New
2 1.55M $47.05M 27.64%
27.64%
New
3 583.59K $44.05M 25.88%
25.88%
New
4 1.58M $24.34M 14.30%
14.30%
New
5 361.25K $4.28M 2.52%
2.52%
New
6 120.47K $2.77M 1.63%
1.63%
New

FAQ

What did Remedium Capital Partners, LLC buy in 2025-Q4?

In its 2025-Q4 13F filing, Remedium Capital Partners, LLC reported 6 equity positions worth $170.21M in aggregate; its largest disclosed positions were SYRE ($47.71M), ORKA ($47.05M), APGE ($44.05M).

How large is Remedium Capital Partners, LLC's portfolio?

Remedium Capital Partners, LLC reported $170.21M of long equity holdings across 6 positions as of 2025-Q4. Top-10 holdings account for 100.0% of reported value.

What is Remedium Capital Partners, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/remedium-capital-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →